杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/08/31 | 1,850 | 1,851 | 1,819 | 1,823 | -31 | -1.7% | 106,300 |
2021/08/30 | 1,832 | 1,854 | 1,828 | 1,854 | +27 | +1.5% | 77,500 |
2021/08/27 | 1,812 | 1,829 | 1,802 | 1,827 | +10 | +0.6% | 80,800 |
2021/08/26 | 1,827 | 1,827 | 1,810 | 1,817 | -10 | -0.5% | 68,100 |
2021/08/25 | 1,848 | 1,848 | 1,821 | 1,827 | -11 | -0.6% | 93,600 |
2021/08/24 | 1,843 | 1,853 | 1,833 | 1,838 | -15 | -0.8% | 104,400 |
2021/08/23 | 1,848 | 1,858 | 1,839 | 1,853 | +20 | +1.1% | 100,600 |
2021/08/20 | 1,844 | 1,849 | 1,828 | 1,833 | -9 | -0.5% | 116,600 |
2021/08/19 | 1,833 | 1,849 | 1,827 | 1,842 | +9 | +0.5% | 94,100 |
2021/08/18 | 1,822 | 1,838 | 1,819 | 1,833 | +14 | +0.8% | 58,400 |
2021/08/17 | 1,824 | 1,830 | 1,814 | 1,819 | +4 | +0.2% | 63,600 |
2021/08/16 | 1,826 | 1,826 | 1,802 | 1,815 | -12 | -0.7% | 61,200 |
2021/08/13 | 1,808 | 1,827 | 1,802 | 1,827 | +21 | +1.2% | 66,600 |
2021/08/12 | 1,811 | 1,814 | 1,801 | 1,806 | +3 | +0.2% | 52,400 |
2021/08/11 | 1,800 | 1,807 | 1,791 | 1,803 | +13 | +0.7% | 103,500 |
2021/08/10 | 1,771 | 1,790 | 1,771 | 1,790 | +17 | +1% | 78,200 |
2021/08/06 | 1,778 | 1,789 | 1,764 | 1,773 | -2 | -0.1% | 82,400 |
2021/08/05 | 1,751 | 1,792 | 1,746 | 1,775 | +20 | +1.1% | 85,600 |
2021/08/04 | 1,750 | 1,766 | 1,731 | 1,755 | -45 | -2.5% | 157,700 |
2021/08/03 | 1,818 | 1,818 | 1,796 | 1,800 | -9 | -0.5% | 31,600 |
2021/08/02 | 1,784 | 1,811 | 1,777 | 1,809 | +38 | +2.1% | 82,600 |
2021/07/30 | 1,780 | 1,781 | 1,762 | 1,771 | -18 | -1% | 99,100 |
2021/07/29 | 1,797 | 1,805 | 1,780 | 1,789 | -9 | -0.5% | 84,800 |
2021/07/28 | 1,772 | 1,804 | 1,772 | 1,798 | +13 | +0.7% | 96,000 |
2021/07/27 | 1,801 | 1,803 | 1,777 | 1,785 | -35 | -1.9% | 138,200 |
2021/07/26 | 1,830 | 1,830 | 1,810 | 1,820 | +11 | +0.6% | 60,100 |
2021/07/21 | 1,842 | 1,842 | 1,803 | 1,809 | +7 | +0.4% | 90,700 |
2021/07/20 | 1,783 | 1,805 | 1,782 | 1,802 | +5 | +0.3% | 74,700 |
2021/07/19 | 1,785 | 1,799 | 1,779 | 1,797 | -5 | -0.3% | 62,900 |
2021/07/16 | 1,796 | 1,808 | 1,790 | 1,802 | -11 | -0.6% | 58,400 |
2021/07/15 | 1,829 | 1,839 | 1,806 | 1,813 | -12 | -0.7% | 99,300 |
2021/07/14 | 1,814 | 1,829 | 1,806 | 1,825 | +17 | +0.9% | 77,500 |
2021/07/13 | 1,809 | 1,812 | 1,796 | 1,808 | +4 | +0.2% | 85,300 |
2021/07/12 | 1,781 | 1,804 | 1,778 | 1,804 | +45 | +2.6% | 114,000 |
2021/07/09 | 1,727 | 1,765 | 1,725 | 1,759 | +6 | +0.3% | 188,500 |
2021/07/08 | 1,763 | 1,767 | 1,753 | 1,753 | -19 | -1.1% | 132,400 |
2021/07/07 | 1,788 | 1,788 | 1,765 | 1,772 | -19 | -1.1% | 168,100 |
2021/07/06 | 1,817 | 1,817 | 1,787 | 1,791 | -14 | -0.8% | 133,700 |
2021/07/05 | 1,830 | 1,834 | 1,805 | 1,805 | -25 | -1.4% | 91,000 |
2021/07/02 | 1,836 | 1,841 | 1,826 | 1,830 | -2 | -0.1% | 113,700 |
2021/07/01 | 1,823 | 1,833 | 1,818 | 1,832 | +20 | +1.1% | 140,400 |
2021/06/30 | 1,822 | 1,825 | 1,801 | 1,812 | +4 | +0.2% | 151,800 |
2021/06/29 | 1,801 | 1,814 | 1,789 | 1,808 | -9 | -0.5% | 155,300 |
2021/06/28 | 1,815 | 1,819 | 1,801 | 1,817 | +10 | +0.6% | 139,600 |
2021/06/25 | 1,813 | 1,817 | 1,794 | 1,807 | +14 | +0.8% | 286,000 |
2021/06/24 | 1,764 | 1,799 | 1,764 | 1,793 | +39 | +2.2% | 337,700 |
2021/06/23 | 1,753 | 1,771 | 1,750 | 1,754 | +6 | +0.3% | 184,100 |
2021/06/22 | 1,732 | 1,749 | 1,719 | 1,748 | +42 | +2.5% | 210,700 |
2021/06/21 | 1,705 | 1,719 | 1,699 | 1,706 | -24 | -1.4% | 173,300 |
2021/06/18 | 1,746 | 1,754 | 1,730 | 1,730 | -15 | -0.9% | 194,500 |
901~
950
件表示中 / 3694件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 146,400円 | +8.8% | +99.9% | 3.55% | 9.35倍 | 0.65倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ジーエヌアイ | 231,600円 | +21.7% | +999.9% | 0.00% | 9.64倍 | 3.19倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
持田薬 | 305,000円 | +3.0% | +27.5% | 2.62% | 19.31倍 | 0.84倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
栄研化 | 220,600円 | +0.4% | -8.4% | 2.40% | 28.32倍 | 1.60倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
ネクセラファーマ | 87,800円 | +20.3% | - | 0.00% | 154.85倍 | 1.15倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム